We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Micropshere Agent Used with Echocardiography Provides Results Comparable to SPECT

By MedImaging International staff writers
Posted on 25 Feb 2009
Print article
A new study concluded that a new microsphere contrast agent used in echocardiography is well tolerated, and that its diagnostic performance in chest pain patients is comparable with single photon emission computed tomography (SPECT) perfusion imaging.

Acusphere, Inc. (Watertown, MA, USA) reported that the study summarized the phase III clinical trial results for Imagify (perflubutane polymer microspheres) for injectable suspension, a cardiovascular drug for the detection of coronary artery disease, the leading cause of death in the United States.

The study was led by Dr. Roxy Senior, consultant cardiologist and director of cardiac research, department of cardiovascular medicine and Institute of Postgraduate Medical Education and Research at Northwick Park Hospital (Harrow, Middlesex, UK), among others. Dr. Senior was the lead clinical investigator for Acusphere's clinical trials for Imagify.

Acusphere is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microsphere technology. The company's lead product candidate, Imagify, is a cardiovascular drug for the detection of coronary artery disease, the leading cause of death in the United States, for which a New Drug Application (NDA) was submitted to the U.S. Food & Drug Administration (FDA) in April 2008 and filed in June 2008. Imagify is designed to enable ultrasound to compete more effectively with nuclear stress testing, the leading procedure for detecting coronary artery disease.

It is estimated that more than 10 million procedures are done each year in the United States to detect coronary artery disease. Imagify and the company's other product candidates were created using proprietary technology that enables Acusphere to control the porosity and size of nanoparticles and microspheres in a versatile manner that allows them to be customized to address the delivery needs of a variety of drugs.

The study was published in the January 2009 issue of the European Journal of Echocardiography.

Related Links:

Acusphere
Northwick Park Hospital


New
Gold Member
X-Ray QA Meter
T3 AD Pro
DRF DR & Remote Fluoroscopy Solution
CombiDiagnost R90
Imaging Table
CFPM201
Silver Member
Radiographic Positioning Equipment
2-Step Multiview Positioning Platform

Print article
Radcal

Channels

Radiography

view channel
Image: The new X-ray detector produces a high-quality radiograph (Photo courtesy of ACS Central Science 2024, DOI: https://doi.org/10.1021/acscentsci.4c01296)

Highly Sensitive, Foldable Detector to Make X-Rays Safer

X-rays are widely used in diagnostic testing and industrial monitoring, from dental checkups to airport luggage scans. However, these high-energy rays emit ionizing radiation, which can pose risks after... Read more

MRI

view channel
Image: The scans revealed a new dimension of brain network organization in humans (Photo courtesy of Georgia State University/TReNDS Center Research)

New Approach Identifies Signatures of Chronic Brain Disorders Using fMRI Scans

Traditional studies of brain function, often using fMRI scans to detect brain activity patterns, have shown promise in identifying changes in individuals with chronic brain disorders like schizophrenia.... Read more

Nuclear Medicine

view channel
Image: Example of AI analysis of PET/CT images (Photo courtesy of Academic Radiology; DOI: 10.1016/j.acra.2024.08.043)

AI Analysis of PET/CT Images Predicts Side Effects of Immunotherapy in Lung Cancer

Immunotherapy has significantly advanced the treatment of primary lung cancer, but it can sometimes lead to a severe side effect known as interstitial lung disease. This condition is characterized by lung... Read more

General/Advanced Imaging

view channel
Image: Cleerly offers an AI-enabled CCTA solution for personalized, precise and measurable assessment of plaque, stenosis and ischemia (Photo courtesy of Cleerly)

AI-Enabled Plaque Assessments Help Cardiologists Identify High-Risk CAD Patients

Groundbreaking research has shown that a non-invasive, artificial intelligence (AI)-based analysis of cardiac computed tomography (CT) can predict severe heart-related events in patients exhibiting symptoms... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.